Literature DB >> 17005220

Introducing Vi polysaccharide typhoid fever vaccine to primary school children in North Jakarta, Indonesia, via an existent school-based vaccination platform.

M D Agtini1, R L Ochiai, R Soeharno, H J Lee, J Sundoro, S R Hadinegoro, O P Han, L Tana, F X S Halim, L Ghani, W Lestari, F X Sintawati, N Kusumawardani, R Malik, T S Santoso, M Nadjib, S Soeroso, F Wangsasaputra, M Ali, B Ivanoff, C M Galindo, T Pang, J D Clemens, A Suwandono, C J Acosta.   

Abstract

OBJECTIVES: To report results on coverage, safety and logistics of a large-scale, school-based Vi polysaccharide immunization campaign in North Jakarta.
METHODS: Of 443 primary schools in North Jakarta, Indonesia, 18 public schools were randomly selected for this study. Exclusion criteria were fever 37.5 degrees C or higher at the time of vaccination or a known history of hypersensitivity to any vaccine. Adverse events were monitored and recorded for 1 month after immunization. Because this was a pilot programme, resource use was tracked in detail.
RESULTS: During the February 2004 vaccination campaign, 4828 students were immunized (91% of the target population); another 394 students (7%) were vaccinated during mop-up programmes. Informed consent was obtained for 98% of the target population. In all, 34 adverse events were reported, corresponding to seven events per 1000 doses injected; none was serious. The manufacturer recommended cold chain was maintained throughout the programme.
CONCLUSIONS: This demonstration project in two sub-districts of North Jakarta shows that a large-scale, school-based typhoid fever Vi polysaccharide vaccination campaign is logistically feasible, safe and minimally disruptive to regular school activities, when used in the context of an existing successful immunization platform. The project had high parental acceptance. Nonetheless, policy-relevant questions still need to be answered before implementing a widespread Vi polysaccharide vaccine programme in Indonesia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17005220     DOI: 10.1016/j.puhe.2006.06.008

Source DB:  PubMed          Journal:  Public Health        ISSN: 0033-3506            Impact factor:   2.427


  4 in total

Review 1.  The impact of new vaccine introduction on immunization and health systems: a review of the published literature.

Authors:  Terri B Hyde; Holly Dentz; Susan A Wang; Helen E Burchett; Sandra Mounier-Jack; Carsten F Mantel
Journal:  Vaccine       Date:  2012-08-29       Impact factor: 3.641

2.  25 years after Vi typhoid vaccine efficacy study, typhoid affects significant number of population in Nepal.

Authors:  Deepak Bajracharya; M Imran Khan; Alfred Pach; Parisha Shrestha; Nilesh Joshi; Shyam R Upreti; Thomas Wierzba; Mahesh Puri; Sushant Sahastrabuddhe; R Leon Ochiai
Journal:  PLoS One       Date:  2014-01-06       Impact factor: 3.240

3.  Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine.

Authors:  Bernie Endyarni Medise; Soedjatmiko Soedjatmiko; Iris Rengganis; Hartono Gunardi; Rini Sekartini; Sukamto Koesno; Hindra Irawan Satari; Sri Rezeki Hadinegoro; Jae Seung Yang; Jean-Louis Excler; Sushant Sahastrabuddhe; Mita Puspita; Rini Mulia Sari; Novilia Sjafri Bachtiar
Journal:  PLoS One       Date:  2019-02-13       Impact factor: 3.240

4.  Public acceptance and willingness-to-pay for a future dengue vaccine: a community-based survey in Bandung, Indonesia.

Authors:  Panji Fortuna Hadisoemarto; Marcia C Castro
Journal:  PLoS Negl Trop Dis       Date:  2013-09-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.